Tracking Triple-negative Breast Cancer Evolution Through Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

149 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-14

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative breast cancer (TNBC) who are eligible for neoadjuvant chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

NCT01276899

Triple Negative Breast Cancer

COMPLETED

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

NCT02266420

Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm

COMPLETED NA

Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

NCT06879704

Triple Negative Breast Cancer

RECRUITING NA

Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer

NCT01514565

Breast Cancer

UNKNOWN

Triple Negative Breast Cancer Biomarker Study

NCT01111175

Metastatic Breast Cancer Triple Negative Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triple-Negative Breast Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All included patients

Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:

1. (optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy
2. At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).
3. Biopsy of a metastatic site in the event of disease recurrence.

Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery.

Group Type EXPERIMENTAL

Biopsy

Intervention Type PROCEDURE

Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy

Biopsy (optional)

Intervention Type PROCEDURE

\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy

Biopsy (metastatic)

Intervention Type PROCEDURE

Biopsy of metastatic site to be performed at the time of relapse

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy

Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy

Intervention Type PROCEDURE

Biopsy (optional)

\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy

Intervention Type PROCEDURE

Biopsy (metastatic)

Biopsy of metastatic site to be performed at the time of relapse

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-years or older
2. Patients with histological confirmation of invasive breast cancer with known receptor status suitable for neoadjuvant chemotherapy as assessed by the local investigator
3. Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by ≤1% of positive staining on immunohistochemistry
4. Human epidermal growth factor receptor 2 (HER2)-negative as defined by American Society of Clinical Oncology / College of American Pathologists guidelines
5. T1c-4 tumours (including inflammatory cancers), with any nodal status non candidate for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided that all sites are HER2-negative and at least one site is ER- and PR-negative.
6. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
7. Patient with social insurance coverage

Exclusion Criteria

1. Confirmed metastatic disease at initial presentation
2. Any contraindication to the biopsy procedure
3. Previous or current malignancies of other origin within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin
4. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
5. Individuals deprived of liberty or placed under the authority of a tutor

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No